Part B-2(No overall page limit applied)4. 	CV of the researcherName and identifiers Huuhtanen, Jani JohannesORCID: 0000-0003-2750-4033Google Scholar: T7UqQkEAAAAJEducation 2024 Doctor of Medicine (PhD, approved with distinction on 27th of August 2024) Faculty of Medicine, University of Helsinki, Helsinki, Finland 2021 Licenciate of Medicine (MD)Faculty of Medicine, University of Helsinki, Helsinki, FinlandSpecialization in clinical hematology (2021 - ongoing)Faculty of Medicine, University of Helsinki, Helsinki, FinlandMaster of science (M.Sc) in bioinformatics (2016 – ongoing)School of Electrical Engineering, Aalto University, Espoo, FinlandProfessional working history5/2024 - present	Postdoctoral researcherUniversity of Helsinki4/2020 - present	Specializing Physician in Clinical HematologyDepartment of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland9/2017 – 5/2024	Doctoral ResearcherLaboratory of Prof. Satu Mustjoki, Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandandLaboratory of Ass. Prof. Harri Lähdesmäki, Computational Systems Biology group, Department of Computer Science, Aalto University5/2019 – 8/2019	Visiting ResearcherDr. Mark M. Davis, Department of Immunology and Microbiology, Stanford University5/2017 – 8/2017	Visiting ResearcherDr. Sarah Teichmann, Cellular Genetics Programme, Wellcome Sanger Institute, Cambridge, United Kingdom 5/2016 – 8/2017	Research AssistantHelsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandandLaboratory of Ass. Prof. Harri Lähdesmäki, Computational Systems Biology group, Department of Computer Science, Aalto UniversityResearch output Publications In total 24 peer-reviewed original publications, which are available at: https://pubmed.ncbi.nlm.nih.gov/?term=huuhtanen+jani.H index 16, total citations 1047 (Google Scholar 1st September 2024)First-author publications 1. HUUHTANEN J#, Kasanen H#, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S. Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J Clin Invest. 2023 Mar 15;133(6):e164809. doi: 10.1172/JCI164809. PMID: 36719749; PMCID: PMC10014104.Citations 37 (1.9.24, Google Scholar)2. HUUHTANEN J, Chen L, Jokinen E, Kasanen H, Lönnberg T, Kreutzman A, Peltola K, Hernberg M, Wang C, Yee C, Lähdesmäki H, Davis MM, Mustjoki S. Evolution and modulation of antigen-specific T cell responses in melanoma patients. Nat Commun. 2022 Oct 11;13(1):5988. doi: 10.1038/s41467-022-33720-z. PMID: 36220826; PMCID: PMC9553985.Citations 21 (1.9.24, Google Scholar)3. HUUHTANEN J#, Ilander M#, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. IFN-? with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585. PMID: 36047494; PMCID: PMC9433106.Citations 9 (1.9.24, Google Scholar)4. HUUHTANEN J#, Bhattacharya D#, Lönnberg T, Kankainen M, Kerr C, Theodoropoulos J, Rajala H, Gurnari C, Kasanen T, Braun T, Teramo A, Zambello R, Herling M, Ishida F, Kawakami T, Salmi M, Loughran T, Maciejewski JP, Lähdesmäki H, Kelkka T, Mustjoki S. Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nat Commun. 2022 Apr 11;13(1):1981. doi: 10.1038/s41467-022-29173-z. PMID: 35411050; PMCID: PMC9001660. Citations 31 (1.9.24, Google Scholar)5. Bhattacharya D#, Teramo A#, Gasparini VR#, HUUHTANEN J#, Kim D, Theodoropoulos J, Schiavoni G, Barilà G, Vicenzetto C, Calabretto G, Facco M, Kawakami T, Nakazawa H, Falini B, Tiacci E, Ishida F, Semenzato G, Kelkka T, Zambello R, Mustjoki S. Identification of novel STAT5B mutations and characterization of TCR? signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer J. 2022 Feb 24;12(2):31. doi: 10.1038/s41408-022-00630-8. PMID: 35210405; PMCID: PMC8873566. Citations 27 (1.9.24, Google Scholar)6. Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forstén S, Warfvinge R, Dufva O, Bouhlal J, Dhapola P, Duàn H, Laajala E, Kasanen T, Klievink J, Ilander M, Jaatinen T, Olsson-Strömberg U, Hjorth-Hansen H, Burchert A, Karlsson G, Kreutzman A, Lähdesmäki H, Mustjoki S. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074-w. Epub ahead of print. PMID: 37919606.Citations 8 (1.9.24, Google Scholar)Other publications:7. Kim D#, Park G#, HUUHTANEN J, Lundgren S, Khajuria RK, Hurtado AM, Muñoz-Calleja C, Cardeñoso L, Gómez-García de Soria V, Chen-Liang TH, Eldfors S, Ellonen P, Hannula S, Kankainen M, Bruck O, Kreutzman A, Salmenniemi U, Lönnberg T, Jerez A, Itälä-Remes M, Myllymäki M, Keränen MAI, Mustjoki S. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nat Commun. 2020 May 7;11(1):2246. doi: 10.1038/s41467-020-16115-w. PMID: 32382059; PMCID: PMC7206083. 8. Jokinen E, HUUHTANEN J, Mustjoki S, Heinonen M, Lähdesmäki H. Predicting recognition between T cell receptors and epitopes with TCRGP. PLoS Comput Biol. 2021 Mar 25;17(3):e1008814. doi: 10.1371/journal.pcbi.1008814. PMID: 33764977; PMCID: PMC8023491. 9. Kelkka T, Bhattacharya D#, HUUHTANEN J#, Savola P#, Lönnberg T, Kankainen M, Paalanen K, Tyster M, Lepistö M, Ellonen P, Smolander J, Eldfors S, Yadav B, Khan S, Koivuniemi R, Sjöwall C, Elo LL, Lähdesmäki H, Maeda Y, Nishikawa H, Leirisalo-Repo M, Sokka-Isler T, Mustjoki S. Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Front Immunol. 2020 Nov 19;11:578848. doi: 10.3389/fimmu.2020.578848. PMID: 33329548; PMCID: PMC7732449. 10. Kim D#, Park G#, HUUHTANEN J, Ghimire B, Rajala H, Moriggl R, Chan WC, Kankainen M, Myllymäki M, Mustjoki S. STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia. 2021 Dec;35(12):3430-3443. doi: 10.1038/s41375-021-01296-0. Epub 2021 Jun 1. PMID: 34075200; PMCID: PMC8632689.11. Lee MH, Theodoropoulos J#, HUUHTANEN J#, Bhattacharya D#, Järvinen P, Tornberg S, Nísen H, Mirtti T, Uski I, Kumari A, Peltonen K, Draghi A, Donia M, Kreutzman A, Mustjoki S. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma. Cancer Res Commun. 2023 Jul 18;3(7):1260-1276. doi: 10.1158/2767-9764.CRC-22-0514. PMID: 37484198; PMCID: PMC10361538.12. Dufva O.#, Gandolfi S.#, HUUHTANEN J.*, Dashevsky O.*, Saeed K., Klievink J., Nygren P., Bouhlal J., Lahtela J., Näätänen A., Ghimire B. R., Hannunen T., Ellonen P., Duàn H., Theodoropoulos J., Laajala E., Härkönen J., Pölönen P., Heinäniemi M., Yamano S., Shirasaki R., Barbie D., Roth J., Romee R., Sheffer M., Lähdesmäki H., Lee D. A., De Matos Simoes R., Kankainen M., Mitsiades C. S., Mustjoki S. Single-cell functional genomics of natural killer cell evasion in blood cancers. Immunity ACCEPTED13. Lundgren S#, Keränen MAI#, Kankainen M, HUUHTANEN J, Walldin G, Kerr CM, Clemente M, Ebeling F, Rajala H, Brück O, Lähdesmäki H, Hannula S, Hannunen T, Ellonen P, Young NS, Ogawa S, Maciejewski JP, Hellström-Lindberg E, Mustjoki S. Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia. 2021 May;35(5):1365-1379. doi: 10.1038/s41375-021-01231-3. Epub 2021 Mar 30. PMID: 33785863; PMCID: PMC8102188.14. Jokinen E, Dumitrescu A, HUUHTANEN J, Gligorijevi? V, Mustjoki S, Bonneau R, Heinonen M, Lähdesmäki H. TCRconv: predicting recognition between T cell receptors and epitopes using contextualized motifs. Bioinformatics. 2023 Jan 1;39(1):btac788. doi: 10.1093/bioinformatics/btac788. PMID: 36477794; PMCID: PMC9825763.15. Kelkka T, Tyster M, Lundgren S#, Feng X#, Kerr C#, Hosokawa K#, HUUHTANEN J#, Keränen M, Patel B, Kawakami T, Maeda Y, Nieminen O, Kasanen T, Aronen P, Yadav B, Rajala H, Nakazawa H, Jaatinen T, Hellström-Lindberg E, Ogawa S, Ishida F, Nishikawa H, Nakao S, Maciejewski J, Young NS, Mustjoki S. Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia. Leukemia. 2022 Sep;36(9):2317-2327. doi: 10.1038/s41375-022-01654-6. Epub 2022 Aug 5. PMID: 35927326; PMCID: PMC9417997.16. Brandstoetter T, Schmoellerl J, Grausenburger R, Kollmann S, Doma E, HUUHTANEN J, Klampfl T, Eder T, Grebien F, Hoermann G, Zuber J, Mustjoki S, Maurer B, Sexl V. SBNO2 is a critical mediator of STAT3-driven hematological malignancies. Blood. 2023 Apr 13;141(15):1831-1845. doi: 10.1182/blood.2022018494. PMID: 36630607.17. Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, HUUHTANEN J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. PMID: 36519325; PMCID: PMC10316276.18. Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, HUUHTANEN J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. PMID: 36508699.19. Dufva O#, Pölönen P#, Brück O#, Keränen MAI#, Klievink J, Mehtonen J, HUUHTANEN J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020 Sep 14;38(3):424-428. doi: 10.1016/j.ccell.2020.08.019. Cancer Cell. 2020 Sep 14;38(3):380-399.e13. PMID: 32931743. 20. Davidson S#, Efremova M#, Riedel A, Mahata B, Pramanik J, HUUHTANEN J, Kar G, Vento-Tormo R, Hagai T, Chen X, Haniffa MA, Shields JD, Teichmann SA. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. Cell Rep. 2020 May 19;31(7):107628. doi: 10.1016/j.celrep.2020.107628. PMID: 32433953; PMCID: PMC7242909. 21. Savola P, Martelius T, Kankainen M, HUUHTANEN J, Lundgren S, Koski Y, Eldfors S, Kelkka T, Keränen MAI, Ellonen P, Kovanen PE, Kytölä S, Saarela J, Lähdesmäki H, Seppänen MRJ, Mustjoki S. Somatic mutations and T-cell clonality in patients with immunodeficiency. Haematologica. 2020 Dec 1;105(12):2757-2768. doi: 10.3324/haematol.2019.220889. PMID: 33256375; PMCID: PMC7716374.22. Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, HUUHTANEN J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019 Jan 24. PMID: 30679796; PMCID: PMC6755975. 23. Savola P, Bhattacharya D, HUUHTANEN J. The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome. Semin Hematol. 2022 Jul;59(3):123-130. doi: 10.1053/j.seminhematol.2022.07.004. Epub 2022 Aug 3. PMID: 36115688.24. Assatova B, Willim R, Trevisani C, Haskett G, Kariya KM, Chopra K, Park SR, Tolstorukov MY, McCabe SM, Duffy J, Louissaint A, HUUHTANEN J, Bhattacharya D, Mustjoki S, Koh MJ, Powers F, Morgan EA, Yang L, Pinckney B, Cotton MJ, Crabbe A, Ziemba JB, Brain I, Heavican-Foral TB, Iqbal J, Nemec R, Rider AB, Ford JG, Koh MJ, Scanlan N, Feith DJ, Loughran TP, Kim WS, Choi J, Roels J, Boehme L, Putteman T, Taghon T, Barnes JA, Johnson PC, Jacobsen ED, Greenberg SA, Weinstock DM, Jain S. KLRG1 Cell Depletion As A Novel Therapeutic Strategy In Patients With Mature T-cell lymphoma Subtypes. Clin Cancer Res. 2024 Jan 22. doi: 10.1158/1078-0432.CCR-23-3504. Epub ahead of print. PMID: 38252421.#,*; these authors contributed equallyData, methods, software, and tools • Datasets produced in publications available in public repositories* CML (Huuhtanen et al., JCI 2022): https://zenodo.org/records/10947495* CML (Huuhtanen et al., Leukemia 2024): https://zenodo.org/records/7330586* Melanoma (Huuhtanen et al., Nat Comm 2022 and Huuhtanen et al., JCI 2022): https://zenodo.org/records/6882576* T-LGLL (Huuhtanen et al., Nat Comm 2022): https://zenodo.org/records/4739231• Open source code developed as part of research projects:* GitHub (including 11 repositories linked to mansucripts, https://github.com/janihuuh)* https://github.com/janihuuh/melanomap_manu* https://github.com/janihuuh/cml_stop_manu* https://github.com/janihuuh/cd8_tlgll_manu• T cell receptor specificty tools* https://github.com/emmijokinen/TCRGP* https://github.com/emmijokinen/TCRconv* https://github.com/DaniTheOrange/EPIC-TRACEInvited talks in international conferences 1. Single-cell roadmap of antigen-specific T cell responses in immune checkpoint inhibitor therapies in melanoma patientsHelsinki Single-Cell Transcriptomics Symposium 2019, Helsinki Finland2. Single-cell analysis of immune responses in CMLNordCML meet 2020, Trondheim Norway (held online due to COVID-19 outbreak)3. Antigen-specific responses decoded with TCRGP prediction algorithmTranslation Immunology Symposium 1 2021, Helsinki Finland4. Immune predictors of treatment-free remission success in CML30th Conference of the Polish Society of Hematology and Transfusion Medicine 2022, Bydgoszcz Poland5. Anti-LAG3+anti-PD1 treatment in metastatic melanomaMelaonama Patient Education Network (MPNE) meeting 2023, Brussels Belgium6. Immune signatures in aplastic anemia and T-LGLL9th International Bone Marrow Failure Disease Scientific Symposium 2024, Bethesda USOral conference presentations selected from abstracts1. Functional and Antigen-Specific Characterizatization of Immune Cells at the Single-Cell Level Reveals Convergence of Adaptive and Innate Immunity; European Hematology Association meeting 2023, Frankfurt Germany2. Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS; 63rd American Society of Hematology Annual Meeting 2021, Atlanta, USA3. Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia; 62nd American Society of Hematology Annual Meeting 2020, e-meet4.  T cell landscape of immune aplastic anemia reveals a convergent antigen-specific signature;61st American Society of Hematology Annual Meeting 2019, Orlando (USA) Awards and honours1. Best MD thesis of 2021 (University of Helsinki, Faculty of Medicine)2. PhD thesis approved with distinction (grade awarded to 10% of best theses in the Faculty of Medicine)3. Best abstract by MD/PhD student (European Hematology Association meeting, Frankfurt Germany 2023)4. American Society of Hematology Annual Meeting Abstract Achievement Award 2019, 2020, 2021, 20235. Computational Biology Training in Hematology (CBTH) 2023(12 months mentoring programmed for 10 selected distinguished post-doctoral researcher working in computational hematology with mentors)Research funding and grants (last 3 years)1. Maud Kuistila foundation (Personal grant, 6000 EUR) 20242. Finska Läkaresällskapet (Personal grant, 6000 EUR) 20243. Instumentarium Research Foundation (Personal grant, 6000 EUR) 20244. Orion Research Foundation (Personal grant, 6000 EUR) 20235. K Albin Johanssen Foundation (Personal grant, 8000 EUR) 20236. Biomedicum Foundation (Personal grant, 6000 EUR) 20237. Blood Disease Foundation Finland (Personal grant, 3500 EUR) 20238. Cancer Foundation Finland (Personal grant, 6000 EUR) 20229. Emil Aaltonen Foundation (Personal grant, 5000 EUR) 202210. KAUTE Foundation (Personal grant, 5000 EUR) 202211. Finnish-Norwegian Foundation (Personal grant, 5000 EUR) 2022Research supervision and leadership experience• Nordic AML group, steering group member• Nordic AML group, educational working group secretary• Ph.D. -students (1, ongoing) University of Helsinki, Faculty of Medicine• M.Sc. students (4 finished theses) University of Helsinki, Faculty of Medicine and Aalto University, Department of Computer Science• B.Sc. students (2 finished theses) Aalto University, Department of Computer Science• M.D./Ph.D. students (1 finished summer rotation) University of Helsinki, Faculty of MedicineOther key academic merits• Peer reviewer for journals including Nature Communications; Journal of Clinical Investigations; F1000; Cancer Immunology, Immunotherapy; Annals of Hematology• European Hematology Association 2024 abstract reviewer (Category: Computational Hematology)• Tutor for MD program class of 2016 at the University of Helsinki• Membership in scientific communitieso European Hematology Association, membero American Society for Hematology, membero American Association for Cancer Research, membero Societfy for Immunotherapy of Cancer, membero Finnish Hematology Association, membero Finnish MDS group, membero Finnish AML group, memberScience communication• Research cited in Finnish national media, including YLE, HBL, Tekniikka&Talous, and in Finnish non-specialist medical journals Erikoislääkärilehti, Mediuutiset• Given an invited talk in Melanoma Patient Education Network meeting in Brussels, Belgium 2023• Given an invited talk at chronic myeloid leukemia patients meeting in Helsinki, Finland 20235. 	Capacity of the Participating Organisation(s) 5.1 Template table: Overview of Participating Organisations Organisation rolePICLegal Entity Short NameAcademic organisation(Y/N)Country Name of Supervisor Beneficiary999984738 NKI AVLYThe NetherlandsDr Ton SchumacherAssociated partner linked to a beneficiary (if applicable)     Associated partner for outgoing phase (mandatory for GF)      Associated partner for secondment (optional)     Associated partner for non-academic placement (optional)      Other: ________      5.2 Template table: Capacity of the Participating Organisations Beneficiary (compulsory)Netherlands Cancer Institute, NKI AVL, NetherlandsGeneral description:The Netherlands Cancer Institute (NKI) comprises an internationally acclaimed research institute as well as a dedicated cancer clinic. This combination ensures rapid translation of basic research into clinical applications: today’s research for tomorrow’s cure.Around 600 scientists are currently working at the NKI, together with approximately 150 scientific and 150 administrative support staff members. Our research unites various disciplines; the full spectrum – from fundamental research to clinical research. The NKI is embedded in several (inter)national scientific networks, providing easy access to a broad range of institutes, technologies, and expertise.NKI provides office and laboratory space, access to world-leading core research facilities, necessary equipment, as well as provide administrative, human resource, and IT support to conduct the work outlined in the proposal. NKI provides an exceptionally supportive and comprehensive training program for Postdoctoral scientists including scientific mentorship, leadership training, public engagement opportunities, personal and career coaching.Role and profile of supervisor Dr Ton Schumacher, PhD, is a Senior Member at NKI and professor of Immunotechnology at Leiden University. He is a renowned world leader in the field of T cell responses in cancer and has >30 years of experience in developing technologies to understand T cell specificities. His lab’s research has resulted in >450 peer-reviewed publications cited >85,000 times (h-index of 114), and his seminal work in associating cancer neoantigens with immunotherapy success and the concept of early line immune checkpoint blockade are the foundations of the T-REaCT action. Dr Schumacher is the recipient of the Queen Wilhelmina Cancer Research Award, Meyenburg Cancer Research Award, William B. Coley Award, and Louis Jeantet Prize for Medicine, and Fellow of the AACR and Royal Netherlands Academy of Arts and Sciences. He has successfully mentored >50 PhD students and postdocs, many of whom have started successful independent research labs internationally. To translate the lab’s research findings, Dr Schumacher has founded 7 biotechs focusing on the development of novel cancer immunotherapeutic and is a venture partner at Third Rock Ventures.Key research facilities, Infrastructure and Equipment NKI Robotics and Screening CenterThe NKI Robotics and Screening Center (NRSC, https://www.nki.nl/research/facilities-platforms/robotics-screening-center/) has established together with Dr Schumacher lab a globally unique T cell receptor (TCR) gene synthesis platform, allowing generation of defined full TCR pairs at a high throughput (1,000s TCRs per week) with low cost ($3.50 per TCR).NKI Genomics Core FacilityThe Genomics Core Facility (GCF) at NKI offers Next Generation Sequencing services using Illumina sequencing equipment (NovaSeq6000, HiSeq2500, NextSeq550 and MiSeq). In addition to wet lab capacities, GCF also provides data storage and bioinformatics support, including demultiplexing, alignments, differential expression analysis and algorithm building for dedicated solutions in data analysis. Investigators have the option to hand in cells, tissue, tumor, RNA, DNA or prepared sequence libraries for analysis.Previous and current involvement in EU-funded research and training programmes/actions/projectsERC Advanced Grant recipient EU (2011, 2017)6. 	Additional ethics information Insert here text for your proposal7. 	Additional information on security screeningInsert here text for your proposal(NB: Only if you answered yes to one of the questions in the security issues table, with the exception of “Does this activity involved HE associated and/or third countries?”)8. 	Environmental considerations in light of the MSCA Green CharterFor communication and dissemination activities, such as conferences that involve travel, we will prioritize low-emission transportation options and utilize teleconferencing whenever possible. In organizing professional trips, conferences, or events, we will aim to select venues listed in the EU Ecolabel Tourist Accommodation Catalogue, ensuring adherence to high environmental standards. To facilitate this, we will make use of platforms such as Bookdifferent.com, which allows for accommodation choices based on carbon footprint and environmental certifications, and consult the EMAS register to confirm organizations' commitment to improving environmental performance. To further measure and minimize the project’s environmental impact, particularly in terms of travel and procurement, we will employ the European Commission’s Consumer Footprint Calculator. This tool will help us assess the environmental impacts of our consumption patterns and make informed adjustments to travel and purchasing decisions within the project. Additionally, we will use the "Buying Green!" Handbook and the Green Public Procurement (GPP) training toolkit to guide our purchasing choices, enabling the selection of products and services with reduced environmental impact.In conclusion, the project aligns with the MSCA Green Charter principles, utilizing a comprehensive set of tools and guidelines provided by the European Commission. These measures demonstrate our commitment not only to advancing scientific research but also to ensuring its alignment with Europe’s broader sustainability goals.9.	Required for Global Fellowships only: Letter(s) of commitment from associated partners (hosting the of outgoing phase)Insert here text for your proposal